Pheno Therapeutics Ltd has been launched in the UK with Series A funding of £5 million to develop new treatments for multiple sclerosis that would halt progression of the disease by targeting the nervous system. Current therapies mainly focus on modulating the immune system in order to reduce the severity and frequency of relapses.
